To Evaluate the Safety and Efficacy of SPH3127 on Treating Mild-moderate Essential Hypertension Patients: A Randomized, Double-Blinded, Dose-Exploration and Placebo-Controlled Study
Latest Information Update: 19 Jul 2024
At a glance
- Drugs SPH 3127 (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Shanghai Pharmaceuticals Holding
- 01 Jul 2024 Results of efficacy and safety of SPH3127 , published in the Hypertension Research
- 11 Nov 2021 Status changed from recruiting to completed.
- 01 Nov 2019 Status changed from not yet recruiting to recruiting.